Treatment of invasive bladder cancer: Lessons from the past and perspective for the future

Japanese Journal of Clinical Oncology

Volumn 34, Issue 6, 2004, Pages 295-306

  Tsukamoto, Taiji ^a   Kitamura, Hiroshi ^a   Takahashi, Atsushi ^a   Masumori, Naoya ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder cancer; Chemotherapy; Invasive; Radiation; Surgery

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; PACLITAXEL; TUMOR MARKER; VINBLASTINE; M VAC PROTOCOL; M-VAC PROTOCOL;

ANEMIA; ASTHENIA; BLADDER CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; CYSTECTOMY; DIAGNOSTIC IMAGING; DRUG FATALITY; EARLY CANCER; FEBRILE NEUTROPENIA; FEVER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LEUKOPENIA; META ANALYSIS; MUCOSA INFLAMMATION; NEUTROPENIA; PATIENT MONITORING; PELVIS LYMPHADENECTOMY; QUALITY CONTROL; RADIOSENSITIVITY; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TRANSURETHRAL RESECTION; TREATMENT INDICATION; ADJUVANT CHEMOTHERAPY; BLADDER TUMOR; LYMPHADENECTOMY; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; CYSTECTOMY; DOXORUBICIN; HUMANS; LYMPH NODE EXCISION; METHOTREXATE; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 6044221528     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh048     Document Type: Review

References (102)

1. Kakizoe T, Yamaguchi N, Mitsuhashi F, Koshiji M, Oshima A, Ohtaka M. Cancer Statistics in Japan - 2001. Tokyo: Foundation for Promotion of Cancer Research, 2001, p. 38.
2. Schoenberg M. Management of invasive and metastatic bladder cancer. In Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr, editors: Campbell's Urology, 8th edn. Philadelphia: WB Saunders Co, 2002, pp 2803-17.
3. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66.
4. Advanced bladder cancer (ABC) meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 2003;361:1927-34.
5. The Japanese Urological Association and Japanese Society of Pathology. The General Rules for Clinical and Pathological Studies on Bladder Cancer, 3rd edn. Tokyo: Kaneharashuppan, 2001.
6. Soloway MS, Soffer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002;167:1573-83.
7. van der Meijden A, Sylvester R, Collette L, Bono A, Kate FT. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: A combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol 2000;164:1533-7.
8. Jichlinski P. New diagnostic strategies in the detection and staging of bladder cancer. Curr Opin Urol 2003;13:351-5.
9. Barentsz JO, Witjes A, Ruijs JHJ. What is new in bladder cancer imaging. Urol Clin N Am 1997;24:583-602.
10. Shvarts O, Han KR, Seltzer M, Pantuck AJ, Belldegrun AS. Positron emission tomography in urologic oncology. Cancer Control 2002;9:335-42.
11. Shigyo M, Sugano K, Tobisu K, Tsukamoto T, Sekiya T, Kakizoe T. Molecular followup of newly diagnosed bladder cancer using urine samples. J Urol 2001;166:1280-5.
12. Quek ML, Quinn DI, Daneshmad S, Stein JP. Molecular prognostication in bladder cancer - a current perspective. Eur J Cancer 2003;39:1501-10.
13. Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: A retrospective study of a homogeneous patient cohort. J Urol 1999;161:1494-7.
14. Dalbagni G, Genega E, Hashibe M, Zhang Z, Russo P, Herr H, et al. Cystectomy for bladder cancer: A contemporary series. J Urol 2001;165: 1111-6.
15. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
16. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21: 690-6.
17. Nishiyama H, Habuchi T, Watanabe J, Teramukai S, Tada H, Ono Y, et al. Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: A survey including 1131 patients treated during 1990-2000 in Japan. Eur Urol 2004;45:176-81.
18. Takahashi A, Tsukamoto T, Tobisu K, Shinohara N, Satoh K, Tomita Y, et al. Radical cystectomy for invasive bladder cancer: Results of multi-institutional pooled analysis. Jpn J Clin Oncol 2004;34:14-9.
19. Skinner DG, Stein JP, Lieskovsky G, Skinner EC, Boyd SD, Figueroa A, et al. 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol 1998;33(Suppl 4):25-6.
20. Esrig D, Freeman JA, Elmajian DA, Stein JP, Chen S, Groshen S, et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol 1996;156:1071-6.
21. Erckert M, Stenzl A, Falk M, Bartsch G. Incidence of urethral tumor involvement in 910 men with bladder cancer. World J Urol 1996;14:3-8.
22. Kakizoe T, Tobisu K. Transitional cell carcinoma of the urethra in men and women associated with bladder cancer. Jpn J Clin Oncol 1998;28: 357-9.
23. Hickey DP, Soloway MS, Murphy WM. Selective urethrectomy following cystoprostatectomy for bladder cancer. J Urol 1986;136:828-30.
24. Lin DW, Herr HW, Dalbagni G. Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. J Urol 2003;169: 961-3.
25. Hautmann RE, Miller K, Steiner U, Wenderroth U. The ileal neobladder: 6 years of experience with more than 200 patients. J Urol 1993;150:40-5.
26. Studer UE, Danuser H, Merz VW, Springer JP, Zingg EJ. Experience in 100 patients with an ileal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment. J Urol 1995;154:49-56.
27. Freeman J, Tarter TA, Esrig D, Stein JP, Elmajian DA, Chen SC, et al. Urethral recurrence in patients with orthotopic ileal neobladders. J Urol 1996;156:1615-9.
28. Tobisu K, Kanai Y, Sakamoto M, Fujimoto H, Doi N, Horie S, et al. Involvement of the anterior urethra in male patients with transitional cell carcinoma of the bladder undergoing radical cystectomy with simultaneous urethrectomy. Jpn J Clin Oncol 1997;27:406-9.
29. Coloby PJ, Kakizoe T, Tobisu K. Sakamoto M. Urethral involvement in female bladder cancer patients: Mapping of 47 consecutive cysto-urethrectomy specimens. J Urol 1994;152:1438-42.
30. Stenzl A, Draxl H, Posch B, Colleselli M, Falk M, Bartsch G. The risk of urethral tumors in female bladder cancer: Can the urethra be used for orthotopic reconstruction of the lower urinary tract? J Urol 1995;153:950-5.
31. Stein JP, Ginsberg DA, Skinner DG. Indications and technique of the orthotopic neobladder in women. Urol Clin North Am 2002;29:725-34.
32. Shekarriz B, Pontes JE. Management of poor risk patients with muscle-invasive transitional cell carcinoma of the bladder. AUA Update Series 2001;20:90-5.
33. Shekarriz B, Shekarriz H, Upadhyay J, Banerjee M, Becker H, Pontes JE, et al. Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer 1999;85:998-1003.
34. Nishiyama N, Masumori N, Satoh E, Takahashi A, Itoh N, Tsukamoto T. Role of cystectomy for patients with invasive bladder cancer having metastasis. Hinyoki Geka 2003;16:1195-9 (in Japanese).
35. Bochner BH, Herr HW, Reuter VE. Impact of separate versus en block pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J Urol 2001;169:2295-6.
36. Poulsen AL, Horn T, Steven K. Radical cystectomy: Extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 1998;160:2015-20.
37. Leissner J, Ghoneim MA, Abol-Enein H, Thuroff JW, Franzaring L, Fisch M, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: Results of a prospective multicenter study. J Urol 2004; 171:139-44.
38. Oosterlinck W, Lobel B, Jakse G, Malmstrom P-U, Stockle M, Sternberg C. Guidelines on bladder cancer. European Association of Urology Guidelines. Arnhem (the Netherlands): European Association of Urology, 2001, p.12.
39. Leissner L, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 2000;85:817-23.
40. Weingarter K, Ramaswamy A, Bittinger A, Gerharz EW, Voge D, Riedmiller H. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J Urol 1996;156:1969-71.
41. Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003;169:943-5.
42. Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en block pelvic lymphadenectomy: The concept of lymph node density. J Urol 2003; 170:35-41.
43. Frank I, Cheville JC, Blute ML, Lohse CM, Nehra A, Weaver AL, et al. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy. Cancer 2003;97:2425-31.
44. Herr HW, Bochner BH, Dalbagni G, Donat M, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002;167:1295-8.
45. Konety BR, Joslyn SA, O'Donnel MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer; analysis of data from the Surveillance, Epidemiology, and End Results Program data base. J Urol 2003;169:946-50.
46. Herr HW. Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 2003;61:105-8.
47. Herr HW. Surgical factors in bladder cancer: More (nodes) + more (pathology) = less (mortality). BJU Int 2003;92:187-8.
48. Cole CJ, Pollack A, Zangers GK, Dinney CP, Swanson DA, von Eschenbach AC. Local control of muscle-invasive bladder cancer: Preoperative radiotherapy versus cystectomy alone. Int J Radiat Oncol Biol Phys 1995;32:331-40.
49. Bochner BH, Montie JE, Lee CT. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: Invasive bladder cancer. Urol Clin N Am 2003;30:777-89.
50. Schuster TG, Smith DC, Montie JE. Pelvic recurrences post cystectomy: current treatment strategies. Sem Urol Oncol 2001;19:45-50.
51. Thalman GN, Fleishman A, Mills RD, Burkhard FC, Markwalder R, Studer UE. Lymphadenectomy in bladder cancer. EAU Update Series 2003;1:100-7.
52. Westney OL, Pister LL, Pettaway CA, Tu S-M, Pollack A, Dinney CPN. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol 1998;159:792-5.
53. Smith JA Jr, Crawford ED, Paradelo JC, Blumenstein B, Herschman BR, Grossman HB, et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: A phase III intergroup study. J Urol 1997;157:805-8.
54. Crawford ED, Wood DP, Petrylak DP, Scott J, Coltman CA Jr, Raghaven D. Southwest Oncology Group studies in bladder cancer. Cancer 2003; 97(Suppl 8):2099-108.
55. Juffs HG, Moore MJ, Tannock F. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 2002;3: 738-47.
56. Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 1991;145:459-64.
57. Studer UE, Bacchi M, Biedermann C, Jaeger P, Kraft R, Mazzucchelli L, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: Results of a prospective randomized trial. J Urol 1994;152:81-4.
58. Stockle M, Wellek S, Meyenburg W, Voges GE, Fischer U, Gertenbach U, et al. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology 1996;48:868-75.
59. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155:495-500.
60. National Cancer Institute, Bethesda, MD, USA. 2003. http://www.nci.nih.gov/search/clinical_trials/ results_clinicaltrials.aspx, accessed October 2003.
61. Martinez-Pineiro JA, Martin GM, Arocena F, Flores N, Roncero CR, Portillo JA, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study. J Urol 1995;153:964-73.
62. Malmström PU, Rintala E, Wahlqvist R, Hellström P, Hellsten S, Hannisdal E. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996;155: 1903-6.
63. Bassi P, Pagano F, Pappagallo G, Cosciani S, Lembo A, Anselmo G, et al. Neoadjuvant M-VAC chemotherapy of invasive bladder cancer: The G.U.O.N.E. multicenter phase II trial. Eur Urol 1998;33(Suppl 1):142.
64. International collaboration of trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC Genito-Urinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder Norwegian Bladder Cancer Study Group and Club Urologico Espanol de Tratamiento Oncologico (CUETO) group. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomized control trial. Lancet 1999;354:533-40.
65. Sherif A, Rintala E, Mestad O, Nilsson J, Holmberg L, Nilsson S, et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer. Nordic Cystectomy Trial 2. Scand J Urol Nephrol 2002;6:419-25.
66. Sternberg CN, Yogoda HI, Watson RC, Herr HW, et al. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcinoma of the uroepithelium; efficacy and patterns of response and relapse. Cancer 1989;64:2448-58.
67. Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, et al. Cisplatin, methotrexate, and vunblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 1985;3:1463-70.
68. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P. Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vunblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992;10: 1066-73.
69. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997;15:2564-9.
70. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with advanced metastatic urothelial tumors. J Clin Oncol 1990;8:1050-5.
71. Loehrer PJ Sr, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: An Eastern Cooperative Oncology Group trial. J Clin Oncol 1994;12:483-8.
72. Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T, and the Japanese Urothelial Cancer Research Group. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: A prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Jpn J Clin Oncol 1998;28:497-506.
73. Bellmunt J, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Batiste-Alentorn E, et al. Phase I-II study of paclitaxel, cisplatin and gemcitabine in advanced transitional cell carcinoma of the urothelium. J Clin Oncol 2000;18:3247-55.
74. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19:2527-33.
75. Meluch AA, Greco FA, Burris HA 3rd, O'Rourke T, Ortega G, Steis RG, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001;15:3018-24.
76. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatinum in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;17:3068-77.
77. Cohen MH, Rothmann M. Correspondence: Gemcitabine and cisplatin for advanced, metastatic bladder cancer. J Clin Oncol 2001;19:1229-31.
78. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003;4:489-97.
79. Bamias A, Aravantionos G, Deliveliotis C, Bafaloukos D, Kalofomos C, Xiros N, et al. Docetaxel and cisplatin with granulocyte-colony stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004;22:220-8.
80. de Wit R. Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 2003;97(Suppl 8):2120-6.
81. Montie JE. Against bladder sparing: Surgery. J Urol 1999;162:452-7.
82. Herr HW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 1987;138:1162-3.
83. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001;19:89-93.
84. Roosen JU, Geertsen U, Hahn H, Jorgen J, Weinreich J, Nissen HM. Tnvasive, high grade transitional cell carcinoma of the bladder treated with transurethral resection - a survival analysis focusing on TUR as monotherapy. Scand J Urol Nephrol 1997;31:39-42.
85. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Calabuig C. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: Long-term follow-up of a prospective study. J Urol 1998;159:95-9.
86. Gospodarowicz MK, Warde PR. A critical review of the role of definitive radiation therapy in bladder cancer. Semin Urol 1993;4:214-26.
87. Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: Multivariate analysis on prognostic factors. J Urol 1996; 155:1897-1902.
88. Scattoni V, Da Pozzo L, Nava L, Broglia L, Galli L, Torelli T, et al. Five-year results of neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy plus radical cystectomy in locally advanced bladder cancer. Eur Urol 1995;28:102-7.
89. Galetti TP, Pontes JE, Montie J, Medendorp SV, Bukowski R. Neoadjuvant intra-arterial chemotherapy in the treatment of advanced transitional cell carcinoma of the bladder: Results and followup. J Urol 1989;142: 1211-5.
90. Jacobs SC, Menashe DS, Mewissen MW, Lipchik EO. Intraarterial cisplatin infusion in the management of transitional cell carcinoma of the bladder. Cancer 1989;64:388-91.
91. Tester W, Caplan R, Heaney J, Venner P. Whittington R, Byhardt R, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14:119-26.
92. Kachnic LA, Kaufman DS, Heney NM, Althausen AF, Griffin PP, Zietman AL, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997;15:1022-9.
93. Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576-83.
94. Rödel C, Gerhard G, Grabenbauer GG. Kühn R, Papadopoulos T, Dunst J, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2002;20:3061-71.
95. Mokarim A, Uetani M, Hayashi N, Sakamoto I, Minami K, Ogawa Y, et al. Combined intraarterial chemotherapy and radiotherapy in the treatment of bladder carcinoma. Cancer 1997;80:1776-85.
96. Sumiyoshi Y, Hashine K, Karashima T, Kasahara K, Inoue Y. Preliminary results of bladder preservation by concurrent intraarterial chemotherapy and radiotherapy for muscle-invasive bladder cancer. Int J Urol 1998;5: 225-9.
97. Miyanaga N, Akaza H, Okumura T, Sekido N, Kawai K, Shimazui T, et al. A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: A prospective pilot study. Int J Urol 2000;7:41-8.
98. Tsukamoto S, Ishikawa S, Tsutsumi M, Nakajima K, Sugahara S. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma. Scand J Urol Nephrol 2002;36:339-43.
99. Kuczyk M, Turkeri L, Hammerer P, Ravery V. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer? Eur Urol 2003;44:57-64.
100. Shipley WU, Kaufman DS, Zehr NM, Heney NM, Lane SC, Thakral HK. et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer Urology 2002;60:62-8.
101. Montie JE. Editorial comment. Urology 2002;60:67.
102. Gospodarowicz M. Radiotherapy and organ preservation in bladder cancer: are we ignoring the evidence? J Clin Oncol 2002;20:3048-50.